Astellas is a major player in the transplantation community. Its products are recognised worldwide in the prevention of organ rejection following kidney, liver and heart transplantation.
Astellas remains focused on investing in its pipeline of potential future immunosuppressant therapies. Through sustained investment in almost 100 European clinical studies, we are continually striving to advance transplant care by developing both new treatment regimes and innovative therapies that target specific pathways.
We are also proud to be able to support patient organisations, helping to offer hope for the future.
NPR17018Ukb – June 2018
Learn more about our therapy areas:
Well established therapies to prevent organ rejection after transplantation
Leading research to satisfy unmet patient needs in urological conditions
Our commitment is to developing first-in-class and best-in-class therapies
Addressing the complex challenges of serious fungal and bacterial infections